Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

The Prognostic Significance of Serum Beta-2 Microglobulin (sβ 2 m) Levels in Patients with Hodgkin Lymphoma (HL): Final Analysis on 915 Patients Treated with ABVD or Equivalent (ABVDeq) Chemotherapy or Combined Modality Therapy (CT/CMT) Focusing to the Determination of Optimal Cut-Offs

Blood (2022) 140 (Supplement 1): 12016–12017.

https://doi.org/10.1182/blood-2022-169972

Published: 2022

Journal Articles

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Steven R. Deitcher, MD, Anas Younes, MD, Luis Fayad, MD, Andre Goy, MD, Nam H. Dang, MD, PhD, A Forman, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Enrique Romaguera, Felipe Samaniego, MD, Jeffrey A. Silverman, Ph.D., Andreas H. Sarris, MD, PhD, Fernando Cabanillas, MD

Blood (2013) 122 (21): 3033.

https://doi.org/10.1182/blood.V122.21.3033.3033

Published: 2013

Journal Articles

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Jorge Enrique Romaguera, MD, Luis Fayad, M.D., Maria Alma Rodriguez, M.D., F.B. Hagemeister, M.D., Barbara Pro, M.D., Peter McLaughlin, M.D., Anas Younes, M.D., Felipe Samaniego, M.D., Andre Goy, M.D., Andreas H. Sarris, M.D., Nam H. Dang, M.D., Luhua Wang, M.D., Hagop M. Kantarjian, M.D., Virginia Beasley, L. Jeffrey Medeiros, M.D., Ruth L. Katz, M.D., Fernando Cabanillas, M.D.

Blood (2006) 108 (11): 2749.

https://doi.org/10.1182/blood.V108.11.2749.2749

Published: 2006

Journal Articles

Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study.

Umberto Vitolo, Emanuele Zucca, Maurizio Martelli, Annalisa Chiappella, Ileana Baldi, Monica Balzarotti, Annarita Conconi, Henry Gomez, Armando Lopez-Guillermo, Giovanni Martinelli, Lorella Orsucci, Vincenzo Pavone, Giuseppe Rossi, Sergio Storti, Mary K. Gospodarowicz, Franco Cavalli, Andreas H. Sarris

Blood (2006) 108 (11): 208.

https://doi.org/10.1182/blood.V108.11.208.208

Published: 2006

Journal Articles

Prospective Management of Primary Testicular Lymphoma (PTL) with Doxorubicin-Based Chemotherapy, Prophylactic Intrathecal (IT) Methotrexate and Radiotherapy (RT), but without Rituximab: Results from IELSG.

Andreas H. Sarris, Umberto Vitolo, Emanuele Zucca, George Z. Rassidakis, Jeffrey Medeiros, Maria Giuseppina Cabras, Alice Di Rocco, Barbara Pro, Mary K. Gospodarowicz, Franco Cavalli

Blood (2006) 108 (11): 2454.

https://doi.org/10.1182/blood.V108.11.2454.2454

Published: 2006

Journal Articles

Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma

Marco Herling, George Z. Rassidakis, Theodoros P. Vassilakopoulos, L. Jeffrey Medeiros, Andreas H. Sarris, on behalf of the International Hodgkin Lymphoma Study Group

Blood (2006) 107 (3): 1240–1241.

https://doi.org/10.1182/blood.V107.3.1240.1240

Published: 2006

Journal Articles

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

Jorge Enrique Romaguera, MD, Luis Fayad, MD, Maria A. Rodriguez, MD, Fredrick B. Hagemeister, MD, Barbara Pro, MD, Peter McLaughlin, MD, Anas Younes, MD, Felipe Samaniego, MD, Andre Goy, MD, Andreas H. Sarris, MD, Ph.D., Nam H. Dang, MD, Ph.D., L. Jeffrey Medeiros, MD, Ruth Katz, MD, Harish Gagneja, MD, Barry I. Samuels, MD, Fernando Cabanillas, MD

Blood (2004) 104 (11): 128.

https://doi.org/10.1182/blood.V104.11.128.128

Published: 2004

Journal Articles

BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens

George Z. Rassidakis, L. Jeffrey Medeiros, Theodoros P. Vassilakopoulos, Simonetta Viviani, Valeria Bonfante, Gianpaolo Nadali, Marco Herling, Maria K. Angelopoulou, Roberto Giardini, Marco Chilosi, Christos Kittas, Timothy J. McDonnell, Gianni Bonadonna, Alessandro M. Gianni, Giovanni Pizzolo, Gerassimos A. Pangalis, Fernando Cabanillas, Andreas H. Sarris

Blood (2002) 100 (12): 3935–3941.

https://doi.org/10.1182/blood.V100.12.3935

Published: 2002

Journal Articles

Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma

Armando López-Guillermo, Fernando Cabanillas, Timothy I. McDonnell, Peter McLaughlin, Terry Smith, William Pugh, Fredrick Hagemeister, M. Alma Rodrı́guez, Jorge E. Romaguera, Anas Younes, Andreas H. Sarris, H. Alejandro Preti, Ming-Seng Lee

Blood (1999) 93 (9): 3081–3087.

https://doi.org/10.1182/blood.V93.9.3081

Published: 1999

Journal Articles

The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas

Armando López-Guillermo, Fernando Cabanillas, Peter McLaughlin, Terry Smith, Fredrick Hagemeister, Marı́a A. Rodrı́guez, Jorge E. Romaguera, Anas Younes, Andreas H. Sarris, H. Alejandro Preti, William Pugh, Ming-Seng Lee

Blood (1998) 91 (8): 2955–2960.

https://doi.org/10.1182/blood.V91.8.2955.2955_2955_2960

Published: 1998

NARROW

The Prognostic Significance of Serum Beta-2 Microglobulin (sβ 2 m) Levels in Patients with Hodgkin Lymphoma (HL): Final Analysis on 915 Patients Treated with ABVD or Equivalent (ABVDeq) Chemotherapy or Combined Modality Therapy (CT/CMT) Focusing to the Determination of Optimal Cut-Offs

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study.

Prospective Management of Primary Testicular Lymphoma (PTL) with Doxorubicin-Based Chemotherapy, Prophylactic Intrathecal (IT) Methotrexate and Radiotherapy (RT), but without Rituximab: Results from IELSG.

Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens

Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma

The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only